These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 25667379)

  • 1. Hyperkalemia develops in some thyroidectomized patients undergoing thyroid hormone withdrawal in preparation for radioactive iodine ablation for thyroid carcinoma.
    Horie I; Ando T; Imaizumi M; Usa T; Kawakami A
    Endocr Pract; 2015 May; 21(5):488-94. PubMed ID: 25667379
    [TBL] [Abstract][Full Text] [Related]  

  • 2. RENAL FUNCTION AND PLASMA RENIN ACTIVITY AS POTENTIAL FACTORS CAUSING HYPERKALEMIA IN PATIENTS WITH THYROID CARCINOMA UNDERGOING THYROID HORMONE WITHDRAWAL FOR RADIOACTIVE IODINE THERAPY.
    Niri T; Horie I; Ando T; Kawahara H; Ueda M; Eto M; Sako A; Ikeuchi Y; Nakao T; Nakashima Y; Shigeno R; Ito A; Nozaki A; Haraguchi A; Natsuda S; Sagara I; Akazawa S; Kamada A; Imaizumi M; Abiru N; Usa T; Kawakami A
    Endocr Pract; 2020 Feb; 26(2):197-206. PubMed ID: 31652100
    [No Abstract]   [Full Text] [Related]  

  • 3. Serum Potassium in Thyroid Cancer Patients With Hypothyroidism During Thyroid Hormone Withdrawal: A Retrospective Study.
    Tangsermvong P; Chamroonrat W; Vittayachokkitikhun S; Sriphrapradang C
    Clin Med Insights Endocrinol Diabetes; 2024; 17():11795514241278519. PubMed ID: 39291259
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk factors for developing hyponatremia in thyroid cancer patients undergoing radioactive iodine therapy.
    Lee JE; Kim SK; Han KH; Cho MO; Yun GY; Kim KH; Choi HY; Ryu YH; Ha SK; Park HC
    PLoS One; 2014; 9(8):e106840. PubMed ID: 25170831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Symptomatic hyponatremia in association with a low-iodine diet and levothyroxine withdrawal prior to I131 in patients with metastatic thyroid carcinoma.
    Shakir MK; Krook LS; Schraml FV; Hays JH; Clyde PW
    Thyroid; 2008 Jul; 18(7):787-92. PubMed ID: 18631009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of thyroid hormone withdrawal on metabolic and cardiovascular parameters during radioactive iodine therapy in differentiated thyroid cancer.
    An JH; Song KH; Kim DL; Kim SK
    J Int Med Res; 2017 Feb; 45(1):38-50. PubMed ID: 27856930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Severe hyponatremia following radioactive iodine therapy in patients with differentiated thyroid cancer.
    Kim SK; Yun GY; Kim KH; Park SK; Choi HY; Ha SK; Park HC
    Thyroid; 2014 Apr; 24(4):773-7. PubMed ID: 24093878
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rapid rise in serum thyrotropin concentrations after thyroidectomy or withdrawal of suppressive thyroxine therapy in preparation for radioactive iodine administration to patients with differentiated thyroid cancer.
    Serhal DI; Nasrallah MP; Arafah BM
    J Clin Endocrinol Metab; 2004 Jul; 89(7):3285-9. PubMed ID: 15240604
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Serum potassium in stage 5 CKD patients on their first presentation in a dialysis service of a county hospital in western Romania.
    Gluhovschi G; Mateş A; Gluhovschi C; Golea O; Gădălean F; Somai M; Ene I; Petrica L; Velciov S
    Rom J Intern Med; 2014; 52(1):30-8. PubMed ID: 25000676
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of preparation method for radioactive iodine therapy on serum electrolytes.
    Takata N; Miyagawa M; Okada T; Kawaguchi N; Fujimoto Y; Kouchi Y; Tsuruoka S; Uwatsu K; Kido T
    Jpn J Radiol; 2023 Nov; 41(11):1247-1254. PubMed ID: 37184818
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of ramipril and telmisartan on serum potassium and its association with cardiovascular and renal events: results from the ONTARGET trial.
    Heerspink HJ; Gao P; de Zeeuw D; Clase C; Dagenais GR; Sleight P; Lonn E; Teo KT; Yusuf S; Mann JF
    Eur J Prev Cardiol; 2014 Mar; 21(3):299-309. PubMed ID: 24191305
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Quality of life and effectiveness comparisons of thyroxine withdrawal, triiodothyronine withdrawal, and recombinant thyroid-stimulating hormone administration for low-dose radioiodine remnant ablation of differentiated thyroid carcinoma.
    Lee J; Yun MJ; Nam KH; Chung WY; Soh EY; Park CS
    Thyroid; 2010 Feb; 20(2):173-9. PubMed ID: 20151824
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prevalence and severity of hyponatremia and hypercreatininemia in short-term uncomplicated hypothyroidism.
    Baajafer FS; Hammami MM; Mohamed GE
    J Endocrinol Invest; 1999 Jan; 22(1):35-9. PubMed ID: 10090135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment with patiromer decreases aldosterone in patients with chronic kidney disease and hyperkalemia on renin-angiotensin system inhibitors.
    Weir MR; Bakris GL; Gross C; Mayo MR; Garza D; Stasiv Y; Yuan J; Berman L; Williams GH
    Kidney Int; 2016 Sep; 90(3):696-704. PubMed ID: 27350174
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antihypertensive Medications and the Prevalence of Hyperkalemia in a Large Health System.
    Chang AR; Sang Y; Leddy J; Yahya T; Kirchner HL; Inker LA; Matsushita K; Ballew SH; Coresh J; Grams ME
    Hypertension; 2016 Jun; 67(6):1181-8. PubMed ID: 27067721
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Levothyroxine-induced serum free thyroxine response following radioactive iodine administration in patients thyroidectomized for differentiated thyroid cancer: A randomized controlled trial.
    Marina M; Maglietta G; De Filpo G; Aloe R; Gnocchi C; Iezzi E; Caminiti C; Ceresini G
    Endocrine; 2022 Aug; 77(2):340-348. PubMed ID: 35751777
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preparation for radioactive iodine therapy is not a risk factor for the development of hyponatremia in thyroid cancer patients.
    Kim J; Cho SG; Kang SR; Kwon SY; Cho DH; Cho JS; Song HC
    Medicine (Baltimore); 2017 Feb; 96(5):e6004. PubMed ID: 28151897
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of Patiromer on Serum Potassium Level in Patients With Hyperkalemia and Diabetic Kidney Disease: The AMETHYST-DN Randomized Clinical Trial.
    Bakris GL; Pitt B; Weir MR; Freeman MW; Mayo MR; Garza D; Stasiv Y; Zawadzki R; Berman L; Bushinsky DA;
    JAMA; 2015 Jul; 314(2):151-61. PubMed ID: 26172895
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of factors causing hyperkalemia.
    Takaichi K; Takemoto F; Ubara Y; Mori Y
    Intern Med; 2007; 46(12):823-9. PubMed ID: 17575373
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-related quality-of-life study in patients with carcinoma of the thyroid after thyroxine withdrawal for whole body scanning.
    Chow SM; Au KH; Choy TS; Lee SH; Yeung NY; Leung A; Leung A; Leung HL; Shek CC; Law SC
    Laryngoscope; 2006 Nov; 116(11):2060-6. PubMed ID: 17075410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.